News Supporting the era of green pharmaceuticals in the UK According to a report by the Office of Health Economics (OHE), commissioned by the Association of th
News BMS, J&J give up on milvexian for acute coronary syndrome BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
